Aggrenox Doesn't Apply In Provigil Pay-For-Delay Suit: Teva

Law360, New York (April 2, 2015, 7:07 PM EDT) -- Teva Pharmaceutical Industries Ltd. on Thursday urged a Pennsylvania federal judge in a pay-for-delay suit over subsidiary Cephalon Inc.’s Provigil narcolepsy drug to ignore the plaintiffs' assertion that a decision in Aggrenox antitrust litigation means that the court should deny its motion to dismiss, saying they misread the opinion.

The pharmaceutical giant said in a letter that the argument made by direct purchaser plaintiffs —  such as King Drug Co. of Florence Inc. — that the Aggrenox opinion shows that resolution of uncertainty caused by patent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.